Align Technology has launched a new Invisalign System in the Philippines, specifically designed for Class II malocclusion in children and teenagers. This innovative treatment integrates mandibular advancement with occlusal blocks, enhancing treatment efficiency and patient comfort.
The new system addresses a significant portion of malocclusions globally, which are prevalent among young patients. By expanding its market presence in the Asia-Pacific region, Align aims to attract more young patients seeking effective orthodontic solutions.
Clinical data indicates that the new system's treatment outcomes are comparable to traditional methods, while the patented SmartTrack™ material used in the occlusal blocks ensures increased comfort and compliance, which are crucial for successful treatment.
This strategic launch not only enhances Align's product offerings but also reinforces its commitment to providing comprehensive orthodontic solutions for growing patients, potentially driving further growth in the company's market share.
Wall Street analysts forecast ALGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGN is 176.70 USD with a low forecast of 150.00 USD and a high forecast of 205.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast ALGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGN is 176.70 USD with a low forecast of 150.00 USD and a high forecast of 205.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 164.920
Low
150.00
Averages
176.70
High
205.00
Current: 164.920
Low
150.00
Averages
176.70
High
205.00
Mizuho
Steven Valiquette
Outperform
maintain
$170 -> $200
2026-01-20
Reason
Mizuho
Steven Valiquette
Price Target
$170 -> $200
AI Analysis
2026-01-20
maintain
Outperform
Reason
Mizuho analyst Steven Valiquette raised the firm's price target on Align Technology to $200 from $170 and keeps an Outperform rating on the shares. Mizuho's annual dental industry survey is more positive than prior years, the analyst tells investors in a research note. The firm upped targets in the dental group as part of its 2026 outlook.
Evercore ISI
Outperform
maintain
$170
2025-12-09
Reason
Evercore ISI
Price Target
$170
2025-12-09
maintain
Outperform
Reason
Evercore ISI says November website traffic data for Align Technology's key website suggests a range "broadly exceeding" Street expectations for Q4 case shipments of about 651,000. If web traffic in December remains in line with October and November and conversion rates hold steady, the data imply an estimated 668,000 cases for Q4, according to the analyst, who has an Outperform rating and $170 price target on Align shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALGN
Unlock Now
Barclays
Hold
initiated
$170
2025-12-08
Reason
Barclays
Price Target
$170
2025-12-08
initiated
Hold
Reason
Barclays initiated coverage of Align Technology with an Equal Weight rating and $170 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Stifel
Buy
maintain
$200
2025-12-05
Reason
Stifel
Price Target
$200
2025-12-05
maintain
Buy
Reason
Stifel reiterated a Buy rating and $200 price target on Align Technology, confirming that Angelalign will implement a price increase on January 1. The firm views the price increase as material to the stock, noting that while some specifics are a little unclear, it will take hold in the U.S., though it is less clear if it will be effective globally. An Angel price increase could further strengthen the case/appeal of Align's pending "zero refinement" plan, which Stifel believes will be priced at roughly $850, with that list price now likely lower than Angelalign, the analyst tells investors in a research note. With Angel's price now moving higher, the argument of Align Technology losing less share or winning back share should strengthen more, the analyst adds.
About ALGN
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
